Scinai Immunotherapeutics Ltd.
NasdaqCM SCNI
Scinai Immunotherapeutics Ltd. Market Capitalization on January 14, 2025: USD 2.94 M
-
Scinai Immunotherapeutics Ltd. 52-week high Market Capitalization is USD 4.99 M on July 15, 2024, which is 70.07% above the current Market Capitalization.
-
Scinai Immunotherapeutics Ltd. 52-week low Market Capitalization is USD 2.28 M on June 12, 2024, which is -22.33% below the current Market Capitalization.
-
Scinai Immunotherapeutics Ltd. average Market Capitalization for the last 52 weeks is USD 3.43 M.
| Date | Market Capitalization | Share Price | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) |
|---|
| CEO | Mr. Amir Reichman M.B.A., M.Sc. |
| IPO Date | May 11, 2015 |
| Location | Israel |
| Headquarters | Jerusalem BioPark Building |
| Employees | 31 |
| Sector | Health Care |
| Industries | |
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email